Pipeline
← Earnings Calls
01
02
03
04 05 06
Tone
Capex
A1 A2 A3 A4 A5
REGN
FY2025 Q4
Improving
Regeneron Pharmaceuticals, Inc. earnings call
Buzzberg read
Regeneron anticipates at least four FDA approvals in 2026, including three new molecular entities.
Regeneron's Q4 2025 call showcased continued strength in Dupixent sales and a clear strategy to defend against Eylea biosimilars by converting to the high-dose Eylea-HD. Management struck an optimistic tone on the pipeline, with multiple high-value readouts expected in oncology and immunology in 2026. The call also surfaced a potential 'Trojan horse' obesity drug concept combining a GLP-1 class medicine with a PCSK9 inhibitor. Dupixent global sales grew 32% YoY to $4.9B, with strong momentum in launches like COPD and chronic spontaneous urticaria.
Buzzberg read Regeneron anticipates at least four FDA approvals in 2026, including three new molecular entities. Regeneron's Q4 2025 call showcased continued strength in Dupixent sales and a clear strategy to defend against Eylea biosimilars by converting to the high-dose Eylea-HD. Management struck an optimistic tone on the pipeline, with multiple high-value readouts expected in oncology and immunology in 2026. The call also surfaced a potential 'Trojan horse' obesity drug concept combining a GLP-1 class medicine with a PCSK9 inhibitor. Dupixent global sales grew 32% YoY to $4.9B, with strong momentum in launches like COPD and chronic spontaneous urticaria. Read full analysisCollapse analysis
Regeneron's Q4 2025 call showcased continued strength in Dupixent sales and a clear strategy to defend against Eylea biosimilars by converting to the high-dose Eylea-HD. Management struck an optimistic tone on the pipeline, with multiple high-value readouts expected in oncology and immunology in 2026. The call also surfaced a potential 'Trojan horse' obesity drug concept combining a GLP-1 class medicine with a PCSK9 inhibitor. Dupixent global sales grew 32% YoY to $4.9B, with strong momentum in launches like COPD and chronic spontaneous urticaria.
- Eylea franchise: Eylea-HD is growing but Eylea 2mg faces inevitable decline against upcoming biosimilars; the PFS approval is the next catalyst for Eylea-HD.
- Linezolic is a major near-term pipeline focus, showing high complete response rates in myeloma and amyloidosis; multiple pivotal studies are underway.
- Management is emphasizing its 'Trojan horse' approach to obesity, combining a GLP-GIP agonist with its PCSK9 antibody for dual weight loss and cholesterol reduction.
Revenue$3.8843BReported
EPS$11.44Reported
Gross margin84.95%Reported
Operating margin22.65%Reported
6 grounded callouts
What matters now
The highest-signal changes from the call.
Clinical Data
First-line metastatic melanoma LAG3 combo readout expected in first half.
Commercial
Liptio adjuvant CSCC launch is off to a great start.
Show 3 more callouts
Regulatory
Eylea HD pre-filled syringe decision expected in late April.
Collaboration
Sanofi collaboration development balance expected fully reimbursed by mid-2026.
Guidance
2026 R&D spend guided to $5.9-6.1 billion, up from 2025.
Reported period
Actuals
| Metric | Reported | Change |
|---|---|---|
| Revenue | $3.8843B | Reported |
| EPS | $11.44 | Reported |
| Gross margin | 84.95% | Reported |
| Operating margin | 22.65% | Reported |
| Free cash flow | $0.922B | Reported |
| Capex | $0.2487B | Reported |
Forward-looking
Forward guidance
| Metric | Period | Range | Midpoint | Status |
|---|---|---|---|---|
| Capex | FY2026 | $1.1B–$1.3B | $1.2B | Guided |
| Gross margin | FY2026 | 83%–84% | 83.5% | Guided |
AI, capex & demand read
Management read
Confident
Management expressed confidence in pipeline breadth, upcoming data readouts, and differentiated product profiles, while acknowledging competitive pressures in certain areas.
Investment and capacity
Management expects 2026 capital expenditures to be in the range of $1.1 to $1.3 billion, primarily related to expanding R&D facilities at Tarrytown headquarters and investments in manufacturing network to support the growing commercial portfolio and pipeline.
all 6 named companies below
Companiesreturns since call
Partners
Partners
Chris Fethmore
Bayer collaboration on Eylea products remains a substantial source of international revenue and profit.
Evidence
“Total buyer collaboration revenue was $319 million, of which $270 million related to our share of net profits outside the United States.”
Partners
Chris Fethmore
Novartis's high sales of Ilaris triggered the highest royalty tier, boosting Regeneron's other revenue.
Evidence
“Alaris net sales exceeded $1.5 billion in 2025, achieving the top royalty tier of 15% for the first time.”
Partners
Chris Fethmore
Sanofi's Dupixent royalty recharge is on track to be fully reimbursed by mid-2026, after which the collaboration economics switch to full profit share. — This is a major profitability inflection point for Regeneron, as its profit share will increase materially in the second half of 2026.
Evidence
“Dupixent's continued strength enabled a rapid reimbursement of the development balance in 2025, which we now expect to be fully reimbursed by mid-2026.”
Competitors
Competitors
Dr. George Yancopoulos
Management highlights a competitor's failure to underscore the uniqueness of Regeneron's antibody discovery technology.
Evidence
“For example, Amgen, using an inferior humanized mouse approach, tried to make a Dupixent that is starting the same receptor as we did, and their antibody completely failed in all their clinical trials.”
Competitors
Marion McCourt
Libtayo is gaining market share in first-line non-small cell lung cancer against competing PD-1 immunotherapies.
Evidence
“new patient market share in this setting greater than Optivo, Tecentric, and Infinsi combined.”
External signals
Supply-chain alpha · 5returns since call
Eylea-HD and Eylea wholesaler inventory levels were elevated by ~$30M at end of Q4 2025, expected to negatively impact Q1 2026 net sales.
Evidence
“wholesaler inventory levels were elevated by approximately 30 million at the end of the fourth quarter for ILEA HD as well as ILEA. We expect first quarter net sales will be negatively impacted as the inventory is absorbed.”
Eylea-HD is now nearly half of total Eylea franchise sales and is growing, but Eylea 2mg is expected to face intense competitive pressure in H2 2026 with biosimilar launches.
Evidence
“While we anticipate continued growth in ILEA-HD this year, ILEA 2 mg will continue to be under competitive pressure, which is expected to intensify the second half of 2026 as multiple biosimilar products are launched in the United States.”
There is a potential 'Trojan horse' strategy for obesity: a co-formulation of a GLP-GIP with PCSK9 inhibitor to address both weight loss and cholesterol, potentially expanding the market by targeting a broader population.
Sanofi's Dupixent royalty recharge is on track to be fully reimbursed by mid-2026, after which the collaboration economics switch to full profit share.
The company is expanding into 'next-generation' therapies, aiming to improve upon its existing blockbusters like Dupixent by leveraging its genetics-based antibody discovery and formulation capabilities.
Methodology & coverage
Management-only analysis. All 6 validated company mentions are shown. Reported actuals and forward guidance are kept separate. Public evidence is limited to eight short attributed quotes. AI-generated analysis can be incomplete or wrong; verify important claims against the original source.